Clinical trial data indicate that the presence of mutated BRAF V600E serves as a negative prognostic indicator for patients diagnosed with metastatic colorectal cancer (mCRC), potentially indicating resistance to EGFR-antibody therapy, particularly in heavily treated individuals [104,105,106]. Here, EGFR is linked to metastatic colorectal cancer.